Radar · Life Sciences in North Rhine Westphalia
Best Life Sciences Companies in North Rhine Westphalia, Germany
The 219 best Life Sciences companies in North Rhine Westphalia, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Better Place.
By Riya SenguptaFinancials
219companies tracked
$1.4Bdisclosed funding
0unicorns
85have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × NORTH RHINE WESTPHALIA
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
50companies analysed
51%cloud-native stacks
2024funding peak (by rounds)
2016median founding year
40median Fliar Index™
207kcombined LinkedIn audience
73%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in North Rhine Westphalia
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Better Place Provider of an AI-powered platform for creating and delivering educational content | $661M | 165 mo ago | Series C | 85 | 2007 | Ralf Ochs Co-Founder | 2 patents Cold water distribution and cooling systems for drinking water supply | — |
| 2 | Emergence Therapeutics Developer of immunotherapeutics for treating cancer | $98M | 54 mo ago | Acquired | 10 | 2019 | — | 45 patents Patents concentrated in health & consumer products | — |
| 3 | Biofrontera Developer of therapies for actinic keratosis using photodynamic therapy 50Market top 29%Funding top 30%News top 34%Moat top 48% All 8 signals ▾Markettop 29% Fundingtop 30% Newstop 34% Moattop 48% Fin. healthtop 50% Growthbottom 43% Globalbottom 43% Techbottom 30% Market: 149 employees (top 13% of Life Sciences) · Revenue ~$41.7M Funding: Raised $93.4M across 10 rounds · 10 rounds over 22 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $93M | 28 mo ago | Public | 149 | 1997 | — | — | — |
| 4 | Singleron Developer of single-cell multi-omics platform for clinical research and molecular diagnosis | $84M | 55 mo ago | Series B | — | 2018 | Jing Zhou Co-Founder | — | — |
| 5 | AiCuris Developer of antiviral and antibacterial therapeutics for infectious diseases | $75M | 103 mo ago | Acquired | 61 61 → 80 (+31%) | 2006 | — | 1,119 patents Antiviral therapeutics targeting herpesvirus nuclear egress and intravaginal drug delivery | — |
| 6 | Abalos Therapeutics Developer of anticancer therapies by stimulating arenavirus | $51M | 56 mo ago | Series A | 22 | 2019 | Marcus Kostka CEO | 38 patents Oncolytic arenavirus vectors engineered for enhanced tumor cell entry and therapy | — |
| 7 | Cardion Specializes in development of novel heart disease and cell transplantation therapies | $46M | 284 mo ago | Deadpooled | — | 1996 | Jurgen Schrader Founder | — | — |
| 8 | Protembis Manufacturer of cerebral protection device 29Moat top 25%Innovation top 32%Funding top 32%Patents top 35% All 7 signals ▾Moattop 25% Innovationtop 32% Fundingtop 32% Patentstop 35% Globalbottom 42% Newsbottom 21% Marketbottom 18% Moat: Editorial + unicorn rating 7/10 · IP moat: 59 patents Innovation: 59 patents (top 43% of patent-holders) · 34 filings since 2022 vs 22 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $42M | 22 mo ago | Public | 3 | 2013 | — | 59 patents Embolic protection devices for aortic arch during cardiovascular interventions | — |
| 9 | Cevec Pharmaceuticals Provider of glyco-optimised human cell lines and gene therapy vectors using proprietary cell expression system | $28M | 58 mo ago | Acquired | 39 | 2001 | — | 208 patents Production and engineering of viral vectors and glyco-modified recombinant therapeutics. | — |
| 10 | Affectis Developer of drugs for the treatment of neurodegenerative and neuroinflammatory diseases | $25M | 194 mo ago | Deadpooled | — | 2004 | Herbert Stadler Founder | — | — |
| 11 | DISCO Pharmaceuticals Developer of target-directed therapeutic modalities for the treatment of cancer 40Growth top 28%Funding top 36%News top 36%Talent top 38% All 9 signals ▾Growthtop 28% Fundingtop 36% Newstop 36% Talenttop 38% Partnerstop 40% Moattop 42% Globalbottom 39% Marketbottom 35% Techbottom 17% Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $21.9M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $22M | 6 mo ago | Seed | — | 2022 | Johannes Heuckmann Chief Operating Officer (COO) and founder | — | — |
| 12 | Protagen Diagnostics for Personalized Medicine in Autoimmune diseases using autoantibody based biomarkers | $20M | 138 mo ago | Acqui-Hired | 20 | 1997 | — | 167 patents Molecular biomarkers for diagnosing and managing autoimmune diseases and cancer immunotherapy | — |
| 13 | Ayoxxa Biosystems Developer of a platform for multiplex protein analysis | $19M | 113 mo ago | Deadpooled | 40 | 2010 | — | 4 patents Patents concentrated in computing, sensing & instrumentation | — |
| 14 | hemovent Developer of equipment for extracorporeal life support | $17M | 71 mo ago | Acquired | 23 | 2013 | — | 54 patents Patents concentrated in health & consumer products | — |
| 15 | PL BioScience Manufacturer of human platelet lysate products for cell culture applications | $13M | 22 mo ago | Series A | 13 | 2015 | Hatim Hemeda CEO | 15 patents Patents concentrated in chemistry & materials | 2 launchs · 1 partnership · 1 award |
| 16 | LenioBio Provider of kit for cell-free protein expression for accelerating drug delivery 50Talent top 28%Funding top 37%Moat top 37%Tech top 39% All 10 signals ▾Talenttop 28% Fundingtop 37% Moattop 37% Techtop 39% Patentstop 41% Growthtop 45% Innovationtop 47% Globalbottom 39% Marketbottom 33% Newsbottom 22% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $13.0M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $13M | 10 mo ago | Series A | 18 18 → 44 (+144%) | 2016 | Remberto Martis Founder & CEO | 20 patents High-throughput membrane protein ligand screening and advanced cell-free protein synthesis platforms | 1 partnership |
| 17 | Miltenyi Biotec Develops tools and products for research and clinical application | $13M | 63 mo ago | Funding Raised | 585 | 1989 | Stefan Miltenyi Founder & MD | 875 patents Advanced cell therapy manufacturing, immune cell engineering, and microfluidic sorting platforms | — |
| 18 | Algiax Speciality company that develops new products for nervous system diseases with focus on neuropathic pain | $12M | 78 mo ago | Series A | 4 | 2011 | Guido Koopmans Co-Founder & CSO | — | — |
| 19 | InterMed Discovery Natural Product lead-discovery | $10M | 209 mo ago | Deadpooled | — | 2006 | Thomas Henkel Co-Founder & Director | 56 patents Small-molecule LXR agonists and HIF‑1 inhibitors for obesity, metabolic and cancer therapies | — |
| 20 | MELAGENIX Developer of molecular diagnostic tests to detect skin cancer | $9M | 75 mo ago | Series A | 9 | 2017 | Daniel Janowski Co-Founder & CPO | — | — |
| 21 | Semalytix Provider of an AI based data analytics solution for reserachers 64AI top 22%Growth top 28%Funding top 36%Talent top 41% All 8 signals ▾AItop 22% Growthtop 28% Fundingtop 36% Talenttop 41% Moattop 48% Techbottom 46% Marketbottom 44% Globalbottom 37% AI: Classified as an AI company · Product described with: ai based, ai-based, artificial intelligence Growth: Headcount 54 → 67 (+24%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 64/100 | $8M | 7 mo ago | Series B | 67 67 → 44 (-34%) | 2015 | Janik Jaskolski Chief Product Officer | — | — |
| 22 | Neuway Pharma Therapies for the treatment of brain diseases using its proprietary CNS drug delivery platform | $7M | 120 mo ago | Public | 18 | 2014 | — | 33 patents Virus-like particle platforms for mRNA and protein therapeutic delivery | — |
| 23 | Coramaze Mitral valve repair system | $6M | 129 mo ago | Series A | 13 | 2013 | Jochen Reinöhl Md Chief Executive Officer | — | — |
| 24 | Nexigen Developer of therapies for oncological indications | $6M | 180 mo ago | Deadpooled | 10 | 2007 | — | 24 patents Protein‑peptide interaction detection platforms for antiviral target discovery and therapeutics | — |
| 25 | New Oncology Provider of pharmacogenomics tests for cancer | $6M | 128 mo ago | Acquired | 30 | 2012 | — | — | — |
| 26 | PROSION Developer of precision medicine technology for cancer treatment | $6M | 50 mo ago | Funding Raised | 10 | 2020 | Mutlu Yonel Co-Founder | — | — |
| 27 | InfanDx Developer of in-vitro diagnostic products for acute and critical care conditions in newborns | $5M | 51 mo ago | Series A | 14 | 2010 | — | 24 patents Metabolic biomarker panels and melt‑curve assays for neonatal encephalopathy, asphyxia, stroke diagnostics | — |
| 28 | Nano4Imaging Developer of MRI compatible guidewires and markers for interventional imaging | $3M | 44 mo ago | Seed | 9 | 2011 | Paul Borm Founder | 24 patents Minimally invasive guide wires and tetrapyrrole MRI contrast agents for medical imaging | 1 partnership |
| 29 | VesselSens Provider of implantable diagnostic sensor system | $3M | 50 mo ago | Funding Raised | — | 2016 | Alexej Domnich CEO | 9 patents Implantable passive RFID pressure sensors for cardiovascular monitoring and fluid dynamics measurement. | — |
| 30 | SenseUP Developer of microbial production strains 21Talent top 35%Moat top 38%Patents top 49%Funding bottom 45% All 7 signals ▾Talenttop 35% Moattop 38% Patentstop 49% Fundingbottom 45% Globalbottom 40% Innovationbottom 37% Marketbottom 23% Talent: 4 named leaders on record Moat: Editorial + unicorn rating 5/10 · IP moat: 14 patents rank vs industry peers · Fliar Intelligence Index 21/100 | $3M | 12 mo ago | Seed | 10 10 → 13 (+30%) | 2015 | Gunter Festel Co-Founder | 14 patents RNA synthesis platforms and aptamer‑based biosensors for diagnostic protein detection | — |
| 31 | Bomedus Develops products to relieve acute and chronic pain | $3M | 126 mo ago | Deadpooled | 11 | 2012 | Tobias Weigl CEO | 2 patents Pain‑relief electrotherapy electrode assemblies for neuromodulation devices | — |
| 32 | Atlas medical technologies Developer of robotic surgical systems with integrated AI for spinal procedures | $3M | 40 mo ago | Series A | 4 | 2018 | Till Gronemeyer Co-Founder | — | — |
| 33 | HBOX Therapies Developer of therapeutics for the treatment of respiratory conditions | $2M | 35 mo ago | Seed | 5 | 2021 | Peter Schlanstein Co-Founder & Managing Director | 3 patents Membrane modules for therapeutic fluid gas enrichment and delivery systems | — |
| 34 | Cellex Developer of stem cells for cancer treatment | $2M | 195 mo ago | Funding Raised | 127 | 2001 | Carla Kreissig Co-CEO | — | — |
| 35 | Niostem Provider of smart wearable device to regrow hair | $2M | 53 mo ago | Seed | 9 | 2019 | Emil Aliev Co-Founder | — | — |
| 36 | Protectimmun Treatments for prevention and therapy of allergic and chronic inflammatory diseases | $2M | 181 mo ago | Seed | — | 2007 | Otto Holst Co-Founder | 17 patents Therapeutic compositions and synthetic arabinogalactans for allergy and inflammatory disease treatment | — |
| 37 | Chimera Biotec Company offering bioanalytical services and immunoassay platforms for ultra sensitive large-molecule… | $1M | 117 mo ago | Funding Raised | 11 | 2001 | Mark Spengler CEO | 20 patents Quantitative detection of biomolecules using conjugated assay reagents and optical devices. | — |
| 38 | LaVision BioTec Developer of microscopes for cell analysis and preclinical imaging | $1M | 53 mo ago | Acquired | 102 | 2000 | — | 40 patents Advanced optical microscopy: light-sheet and single-molecule localization imaging systems | — |
| 39 | IEM Portfolio of devices and software for hypertension management | $759K | 65 mo ago | Funding Raised | — | 1993 | Uwe Korth CEO | — | 2 partnerships |
| 40 | Bitop Develops reagents for bioactive compound, cosmetic active ingredient, and biostabilizer | $608K | 101 mo ago | Funding Raised | 41 | 1993 | Daniel Berger CEO | 201 patents Pharmaceutical formulations for ocular treatments, sirtuin activation, and antiviral solutes. | 1 launch |
| 41 | Evoxx Technologies Developer of enzymes and bio-catalytic processes | $554K | 137 mo ago | Acquired | 15 | 2006 | — | — | — |
| 42 | SeSaM-Biotech Technologies and solutions for protein engineering | $542K | 113 mo ago | Funding Raised | 5 | 2008 | Ulrich Schwaneberg Founder | — | — |
| 43 | DESINO Wheelchair with patented seating system | $534K | 126 mo ago | Deadpooled | — | 2012 | Thyl Junker Co-Founder & Director | 6 patents Active wheelchair seat actuation mechanisms and manual wheelchair propulsion systems | — |
| 44 | Gremse-IT Provider of a software for biomedical image data reconstruction and analysis | $494K | 40 mo ago | Funding Raised | — | 2016 | Felix Gremse Founder & CEO | — | 1 launch |
| 45 | Adhesys Medical Manufacturer of bio-degradable polyurethane-based surgical sealants | $475K | 115 mo ago | Acqui-Hired | 4 | 2013 | — | 61 patents Two-component surgical tissue adhesives and sealant kits for vascular and organ anastomosis | — |
| 46 | LIFE & BRAIN Provides research and development for biomedical and neuroscientific technology platform | $326K | 77 mo ago | Funding Raised | — | 2002 | Markus Nothen Co-Founder & Co-CEO | 83 patents Scalable production platforms for human neural and microglial cell cultures and optical voltage sensing | 1 job opening |
| 47 | Fibrothelium Developer of silk protein derived from silkworm cocoons | $302K | 69 mo ago | Funding Raised | — | 2017 | Hans Leemhuis Chief Executive Officer | 13 patents Silk fibroin biomaterials for medical implants, drug delivery, and therapeutic protein production | — |
| 48 | MedSkin Solutions Developer of home-use skin care products for soft tissue regeneration & wound care | $297K | 68 mo ago | Funding Raised | — | 1997 | Wolfgang Suwelack Founder | — | — |
| 49 | CalTIC Developer of TRPC inhibitors for the treatment of metabolic and pathological cardiac conditions | $289K | 44 mo ago | Seed | — | 2021 | Klaus Dinkel CEO | — | — |
| 50 | Localite Developer of surgical navigation and planning systems | $123K | 44 mo ago | Funding Raised | 15 15 → 17 (+13%) | 1999 | Arno Schmitgen Managing Director | — | — |
Top 12 Life Sciences companies in North Rhine Westphalia
#1
Seed · Cologne, North Rhine Westphalia · founded 2022$21.9Mraised▾
Seed · Cologne, North Rhine Westphalia · founded 2022
Developer of target-directed therapeutic modalities for the treatment of cancer. The company specializes in mapping the surfaceome of cancer cells and develop first-in-class cancer drugs. It identifies proteins and protein communities across the entire cancer cell surface addressing the need for target candidates for both mono- and bi-specific antibodies.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Growth
top 28%Funding
top 36%News
top 36%Talent
top 38%Partners
top 40%Moat
top 42%Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Funding: Raised $21.9M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Seed (Dec 2025)
News: 3 BI events in 12 mo (of 3 tracked, 2 types) · Top themes: Contracts, Funding
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · hiring: BTA/MTA (m/f/d), Financial Accountant – Accounting & Administration
Activity (LinkedIn): 1 partnerships (incl. Amgen) announced in 12 mo
Funding rounds
- Dec 2025Seed$41.9M
- Jan 2024Seed$21.9M
Founders & team
Investors
Sofinnova Partners, Panakes Partners, M Ventures, AbbVie, Ackermans & van Haaren, NRW.Bank
Tech stack
Apache Http ServerIonosJqueryJquery MigrateLightboxMicrosoft 365
#2
Series B · Bielefeld, North Rhine Westphalia · founded 2015 · 67 employees$7.5Mraised▾
Series B · Bielefeld, North Rhine Westphalia · founded 2015 · 67 employees
Semalytix is an AI-based data analytics solution. The company leverages artificial intelligence and machine learning to offers an analytics solution for marketing, business analytics, financial services, and pharmaceutical. The company has developed products like Pharos which has the ability to make decisions based on patients' health data, population data, and more.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
AI
top 22%Growth
top 28%Funding
top 36%Talent
top 41%Moat
top 48%Tech
bottom 46%AI: Classified as an AI company · Product described with: ai based, ai-based, artificial intelligence
Growth: Headcount 54 → 67 (+24%) across vintages · Fresh capital in last 24 mo
Funding: Raised $7.5M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) · Last round Series B (Oct 2025)
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Oct 2025Series B$6.6M
- Feb 2021Series A$2.4M
- Aug 2020Series A$5.1M
- Jan 2019Grant (prize money)$393K
Founders & team
Investors
The Hundert, Fly Ventures, b2venture, Europa, NRW.Bank, Holland Capital
#3
Series A · Dusseldorf, North Rhine Westphalia · founded 2016 · 18 employees$13Mraised▾
Series A · Dusseldorf, North Rhine Westphalia · founded 2016 · 18 employees
Provider of kit for cell-free protein expression for accelerating drug delivery. The company develops ALiCE is the first eukaryotic cell-free protein expression platform for the discovery, development, and production of difficult-to-express proteins. It has active energy regeneration and has components necessary for protein folding, disulfide bonding, and glycosylation.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Talent
top 28%Funding
top 37%Moat
top 37%Tech
top 39%Patents
top 41%Growth
top 45%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $13.0M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) · Last round Grant (prize money) (Jul 2025)
Moat: Editorial + unicorn rating 7/10 · IP moat: 20 patents · 9 curated direct competitors tracked
Audience (LinkedIn): 6k LinkedIn followers — 2.7% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Twost Bioscience) announced in 12 mo
Funding rounds
- Jul 2025Grant (prize money)$4.3M
- Sep 2023Grant (prize money)—
- May 2022Grant (prize money)$2.9M
- Feb 2022Grant (prize money)$56.3K
Founders & team
Investors
EIT Food, Bridford Group, Eureka, EIC Fund, Europa, European Innovation Council
Tech stack
ActivecampaignCloudflareCloudflare Bot ManagementComplianzCore-JsElementor
#4
Public · Aachen, North Rhine Westphalia · founded 2013 · 3 employees$42.5Mraised▾
Public · Aachen, North Rhine Westphalia · founded 2013 · 3 employees
Manufacturer of cerebral protection device It produces a cerebral protection device for use during cardiac surgeries involving the left heart to prevent strokes. Their device consists of an implantable filter system that can be introduced into the aortic arch during minimally invasive procedures which prevent the migration of embolic particles into the cerebral vasculature which prevents strokes.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Moat
top 25%Innovation
top 32%Funding
top 32%Patents
top 35%Global
bottom 42%News
bottom 21%Moat: Editorial + unicorn rating 7/10 · IP moat: 59 patents
Innovation: 59 patents (top 43% of patent-holders) · 34 filings since 2022 vs 22 in 2017-21 · Deep-tech classification: Tech Hardware
Funding: Raised $42.5M across 3 rounds · 3 rounds over 11 yrs (0.3/yr) · Last round Venture Debt (Jul 2024)
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Jul 2024Venture Debt$21.7M
- Mar 2024Series B$35.2M
- Oct 2018Series A$10M
- Jul 2015Seed—
Investors
European Investment Bank, Bmbf, Abiomed, Coparion, TechVision Fonds, IFB Innovationsstarter
#5
Seed · Julich, North Rhine Westphalia · founded 2015 · 10 employees$2.7Mraised▾
Seed · Julich, North Rhine Westphalia · founded 2015 · 10 employees
SenseUp is a developer of microbial production strains. The company uses patented meta sensor technology to screen strains of bacteria, with higher productivity. The technology has applications for train development, SNP identification, library screening, and process dynamics analysis. It also offers a product like amino acids, proteins and peptides, RNA and other natural products.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Talent
top 35%Moat
top 38%Patents
top 49%Funding
bottom 45%Global
bottom 40%Innovation
bottom 37%Talent: 4 named leaders on record
Moat: Editorial + unicorn rating 5/10 · IP moat: 14 patents
Patents: 14 patents matched (strict assignee match) · 8 filings since 2022 vs 6 in 2017-21 · Latest publication 2024
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- May 2025Seed$2.7M
Founders & team
Investors
Capnamic Ventures, CHECK24, Rockstart, b.value AG
#6
Public · Leverkusen, North Rhine Westphalia · founded 1997 · 149 employees$93.4Mraised▾
Public · Leverkusen, North Rhine Westphalia · founded 1997 · 149 employees
Developer of therapies for actinic keratosis using photodynamic therapy. It offers medication focused on protecting and healing skin. The company specializes in dermatology, addressing various skin health concerns. It provides a product portfolio and conducts clinical trials.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Market
top 29%Funding
top 30%News
top 34%Moat
top 48%Fin. health
top 50%Growth
bottom 43%Market: 149 employees (top 13% of Life Sciences) · Revenue ~$41.7M
Funding: Raised $93.4M across 10 rounds · 10 rounds over 22 yrs (0.5/yr) · Last round Post IPO (Feb 2024)
News: 11 BI events in 12 mo (of 114 tracked, 10 types) · -8% YoY · Top themes: Earnings, Acquisition, Regulatory
Funding rounds
- Feb 2024Post IPO$16M
- Nov 2021Post IPO$15M
- Feb 2021Post IPO—
- Jul 2020Post IPO$9.4M
Investors
Land, Rosalind Advisors, Deutsche Balaton
Tech stack
Typo3 CmsPhpBootstrapApache Http ServerSlickJquery
#7
Series A · Aachen, North Rhine Westphalia · founded 2015 · 13 employees$13Mraised▾
Series A · Aachen, North Rhine Westphalia · founded 2015 · 13 employees
Manufacturer of human platelet lysate products for cell culture applications. The company offers a range of platelet lysate products with different safety grades. These products support cell expansion for research, therapeutics, and clinical applications. The company's technology aims to provide solutions for cell culture needs.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers — 2.4% of this cohort's audience
Activity: 2 product launches · 1 partnerships · 1 awards (incl. AVANT BIO) announced in 12 mo
Funding rounds
- Aug 2024Series A$8.5M
- May 2021Series A$4.5M
Founders & team
Investors
Brightlands Venture Partners, Born2Grow, TechVision Fonds, SilverSky LifeSciences, AVANT BIO, Lepure Biotech
Tech stack
Apache Http ServerCart FunctionalityChart.JsCloudflareCloudflare Bot ManagementContact Form 7
#8
Series C · Gronau, North Rhine Westphalia · founded 2007 · 85 employees$660.8Mraised▾
Series C · Gronau, North Rhine Westphalia · founded 2007 · 85 employees
Provider of an AI-powered platform for creating and delivering educational content. The platform offers tools for educators and institutions to design personalized learning experiences. It includes features such as AI course generation, adaptive learning management, and content publishing. The platform aims to make education more accessible and scalable.
Funding rounds
- Aug 2012Conventional Debt$50.1M
- Nov 2011Series C$200M
- May 2010Series C$350M
- May 2009Series C$110.8M
Founders & team
Investors
GE Capital, UBS, Israel Corp, HSBC, VantagePoint Capital Partners, Morgan Stanley
Tech stack
Apache Http ServerBackbone.JsCart FunctionalityCore-JsDropzoneElementor
#9
Series B · Hagen, North Rhine Westphalia · founded 2018$84.5Mraised▾
Series B · Hagen, North Rhine Westphalia · founded 2018
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis. It offers a product portfolio that includes instruments, microfluidic devices, reagents, software analysis, and database solutions that facilitate high-throughput single-cell analysis. It also, offers single cell sequencing services.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 19k LinkedIn followers — 9.3% of this cohort's audience
Funding rounds
- Nov 2021Series B—
- Dec 2020Series A$30M
- Nov 2020Series A$10M
- Sep 2020Series A$30M
Founders & team
Investors
Sherpa Venture Capital, Yuanhe Holdings, China Growth Capital, Frees Fund, CDH, LAV Asset Management
Tech stack
Apache Http ServerAutoptimizeBorlabs CookieCloudflareJqueryJquery Migrate
#10
Acquired · Duisburg, North Rhine Westphalia · founded 2019 · 10 employees$98.2Mraised▾
Acquired · Duisburg, North Rhine Westphalia · founded 2019 · 10 employees
Emergence therapeutics develops immunotherapeutics for treating cancer. The company is developing novel antibody-drug conjugate (ADC) immuno-therapeutics to treat cancers. The company uses proprietary ATAC technology to target Nectin-4 a target for a broad range of cancers.
Funding rounds
- Dec 2021Series A$98.2M
- Nov 2020Seed—
- Nov 2019Seed—
Investors
HTGF, RA Capital Management, Orbimed, Pontifax, Hadean Ventures, Kurma Partners
#11
Series A · Essen, North Rhine Westphalia · founded 2019 · 22 employees$50.8Mraised▾
Series A · Essen, North Rhine Westphalia · founded 2019 · 22 employees
Developer of anticancer therapies by stimulating arenavirus. The company is developing arenavirus-based drug candidates that are used to stimulate the precise specific immune responses and activate immune cells against primary tumors and metastases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Oct 2021Series A$37.6M
- Oct 2019Series A$13.2M
Founders & team
Investors
Seventure Partners, NRW.Bank, Boehringer Ingelheim Venture Fund, Grunderfonds Ruhr, HTGF, Ventura Biomed
Tech stack
Animate.CssApache Http ServerBootstrapContact Form 7FancyboxFont Awesome
#12
Acquired · Cologne, North Rhine Westphalia · founded 2001 · 39 employees$28.4Mraised▾
Acquired · Cologne, North Rhine Westphalia · founded 2001 · 39 employees
Provider of glyco-optimized human cell lines and gene therapy vectors using proprietary cell expression system. The company has ELEVECTA technology for AAV manufacturing, CAP Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. Provides the CAP GT expression platform, a scalable production system for gene therapy vectors. Also offers cell line development and protein expression services.
Funding rounds
- Jul 2021Series E—
- Apr 2019Series D—
- Jul 2015Series C$4.9M
- Oct 2012Series C$3.6M
Investors
NRW.Bank, Creathor Venture, Sparkasse, Midas Group, Peppermint VenturePartners, Danaher
Tech stack
WordpressMysqlPhpThe Seo FrameworkApache Http ServerJquery Migrate
Funding & investor landscape
$1.4Btotal disclosed funding
60companies funded
137disclosed rounds
0rounds last 90 days
Most active investors
Notable founders
Johannes Heuckmann
Chief Operating Officer (COO) and founder · DISCO Pharmaceuticals
Roman Thomas
Co-Founder & CEO · DISCO Pharmaceuticals
Janik Jaskolski
Chief Product Officer · Semalytix
Remberto Martis
Founder & CEO · LenioBio
Hakon Birgisson
Co-Founder & Director of Business Development · LenioBio
Gunter Festel
Co-Founder · SenseUP
Thomas Schwarz
Co-Founder · SenseUP
Hatim Hemeda
CEO · PL BioScience
Ralf Ochs
Co-Founder · Better Place
Joachim Muller
Co-Founder · Better Place
Jing Zhou
Co-Founder · Singleron
Nan Fang
Co-Founder & CEO · Singleron
Prism market signals · Germany · country-scoped Prism corpus, 141,341 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · Germany
How research on Biotechnology is moving in Germany
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,297 Germany-affiliated papers.
research sentiment over time
200820152026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 38% → 41% across 2008–2026.
top research entities
- Heidelberg University85
- German Cancer Research Center49
- Ludwig-Maximilians-Universität München48
- Technical University of Munich43
- Karlsruhe Institute of Technology33
leading researchers
Lennart Hilbert · Henry Reyer · Michael Oster · Nares Trakooljul · Badhe, Pravin · Avon Augustin Nalpadan · Siriluck Ponsuksili · Ralf Nauen
▲
Breakthroughs421 · 32%
▼ 35%→31% share
▼0.9× share momentum0 median citations78% since 2021mostly empirical
Messenger RNA research is surging — German biotech papers rose from 1 to 14, alongside newly emerging Genome (15) and Mutation (13) topics.
rising sub-themes (early→recent)
- Gene3→29
- Mutant3→19
- Transcription (linguistics)3→16
- Messenger RNA1→14
- Immune system1→12
Newly emergingGenome 0→15 · Mutation 0→13 · RNA polymerase II 0→9
Landmark The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets · 4,863 cites
◆
Advancements429 · 33%
33%→33% share
▲1.0× share momentum0 median citations82% since 2021mostly empirical
Gene and Agriculture advancement research is intensifying — papers rose 3→20 and 2→12 respectively, with Downregulation/upregulation newly emerging at 12.
rising sub-themes (early→recent)
- Gene3→20
- Agriculture2→12
- Extracellular1→11
- Immune system1→11
- Transcriptome1→9
Newly emergingDownregulation and upregulation 0→12 · Selection (genetic algorithm) 0→11 · Antibody 0→10
Landmark Regulation of the Voltage Gated K<sup>+</sup> Channel K<sub>v1.3</sub> by Recombinant Human Klot · 5,606 cites
▼
Concerns184 · 14%
▼ 17%→14% share
▼0.8× share momentum0 median citations79% since 2021mostly empirical
Antibiotic resistance and Agriculture concerns are rising simultaneously — papers grew 2→9 and 4→9, with Sustainability newly flagged at 9 papers.
rising sub-themes (early→recent)
- Antibiotic resistance2→9
- Gene1→7
- Agriculture4→9
- Antimicrobial1→4
- Microbiome1→4
Newly emergingContext (archaeology) 0→11 · Sustainability 0→9 · Production (economics) 0→7
Landmark Prebiotic effects: metabolic and health benefits · 2,037 cites
RESEARCH HOTSPOTS · Germany
Where biotechnology is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Munich119 · +0.49
Berlin91 · +0.38
Heidelberg90 · +0.52
Jülich/Bonn72 · +0.41
Karlsruhe34 · +0.30
Aachen23 · +0.51
Dresden22 · +0.54
Stuttgart7 · +0.56
PATENT SIGNAL · Germany
Who's filing biotechnology patents in Germany
Germany biotechnology patent filing is cooling — 53,233 filings from 8,000 assignees (2016–2025), led by Immatics Biotechnologies, BASF Plant Science, BASF SE; annual filings 4819→4267.
53,233 filings8,000 assigneespeak 6040/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Immatics Biotechnologies4875
- BASF Plant Science3993
- BASF SE3545
- Boehringer Ingelheim INT3440
- Merck Patent3137
- MAX Planck Gesellschaft1805
- Evonik Degussa1683
- Amgen RES Munich1665
Common questions
How many Life Sciences companies are there in North Rhine Westphalia, Germany?
Radar tracks 219 indexable Life Sciences companies headquartered in North Rhine Westphalia, Germany that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in North Rhine Westphalia, Germany?
The Life Sciences companies in North Rhine Westphalia, Germany on this list have raised a combined $1.4B in disclosed equity funding across 60 funded companies.
Which is the highest-funded Life Sciences company in North Rhine Westphalia, Germany?
Better Place is the highest-funded Life Sciences company in North Rhine Westphalia, Germany, with $660.8M in disclosed equity funding.
How many Life Sciences companies in North Rhine Westphalia, Germany are funded?
60 of the 219 Life Sciences companies in North Rhine Westphalia, Germany on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in North Rhine Westphalia, Germany?
None of the Life Sciences companies in North Rhine Westphalia, Germany on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in North Rhine Westphalia, Germany Life Sciences companies?
The most active investors in North Rhine Westphalia, Germany Life Sciences companies on this list include Europa, HTGF, Kfw, NRW.Bank, TechVision Fonds.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.